Promoting remyelination is recognized as a novel strategy to foster repair in neurodegenerative demyelinating diseases, such as multiple sclerosis. In this respect, the receptor GPR17, recently emerged as a new target for remyelination, is expressed by early oligodendrocyte precursors (OPCs) and after a certain differentiation stage it has to be downregulated to allow progression to mature myelinating oligodendrocytes. Here, we took advantage of the first inducible GPR17 reporter mouse line (GPR17-iCreER T2 xCAG-eGFP mice) allowing to follow the final fate of
| I N TR ODU C TI ON
Oligodendroglial precursor cells (OPCs), also known as NG2 cells due to their expression of the proteoglycan NG2, are known to proliferate and participate to remyelination during multiple sclerosis. However, while disease progresses, this process becomes progressively less efficient, eventually resulting in blockade of oligodendroglial differentiation and impaired myelin repair (Podbielska, Banik, Kurowska, & Hogan, 2013) . This, in turn, leads not only to overt neurological disturbances due to interruption of impulse transmission, but also to axonal damage and neurodegeneration followed by progression of the remittingrelapsing to the progressive chronic form of the disease. The reasons responsible for the progressive loss of patients' remyelinating abilities are still under study. Thus promoting myelination via a specific action on key molecules involved in OPC maturation has been increasingly recognized as a promising strategy to foster endogenous remyelination, especially in the progressive forms (Rovaris et al., 2006) .
In this respect, the G protein-coupled receptor GPR17 has recently emerged as a key timer of oligodendrogliogenesis. In the intact brain and spinal cord, GPR17 is specifically expressed by a subset of early bipolar NG2 positive (GPR17 1 -NG2 1 ) OPCs, accompanies OPC maturation up to immature/pre-oligodendrocytes and is then downregulated before terminal maturation (Lecca et al., 2008; Ceruti et al., 2009) . Any alterations in this precise expression pattern result in myelination defects (Chen et al., 2009; Fumagalli et al., 2011; Fumagalli et al., 2015) . Pathologically increased levels of GPR17 have been found after focal lysolecithin induced demyelination (Boda et al., 2011) , following brain ischemia in rodents subjected to middle cerebral artery occlusion (MCAO) (Ciana et al., 2006; Lecca et al., 2008) and after traumatic brain injury in both rodents (Boda et al., 2011) and human subjects (Franke et al., 2013) . In initial studies, the mRNA for GPR17 was also found to be increased in the spinal cord of mice with experimental autoimmune encephalomyelitis (EAE) and in the spinal lesions of multiple sclerosis patients (Chen et al., 2009) . The exact significance of persistent GPR17 overexpression in vivo under demyelinating conditions is still unknown.
Our in vitro data suggest that GPR17 aberrant overexpression in OPCs leads to impaired downregulation at late differentiation stages and blockade of cells at immature stages, thus impairing remyelination (Fumagalli, Lecca, & Abbracchio, 2016) . Initial data also suggest that GPR17 overexpression may be due, at least in part, to inflammatory cytokines and chemokines like the stromal derived factor 1 (SDF1), that accumulate at the sites of demyelinating inflamed lesions (Calderon et al., 2006) and can indeed specifically interact with this receptor (Parravicini et al., 2016) . However, a detailed study on GPR17 dysfunction in in vivo conditions associated to demyelination and inflammation is still missing, nor is known whether changes in the pool of GPR17
1 cells contribute to, or contrast, lesion repair.
Here, to shed light on this issue, we used two rodent demyelination models: the autoimmune experimental encephalomyelitis (EAE) model, the most studied animal model of human multiple sclerosis over the past decades, and the cuprizone-induced model, that bypasses the autoimmune component and is more adequate to study the timing of demyelination and remyelination phases (Denic et al., 2011) . To detail the final fate of the GPR17-expressing cells and to unveil whether they indeed become functionally mature myelinating oligodendrocytes, we took advantage of the first inducible fluorescent GPR17 reporter mouse line for fate mapping studies (GPR17-iCreER T2 xCAG-eGFP mice), where, upon tamoxifen treatment, all GPR17-expressing cells at that specific moment become permanently fluorescent, and can be traced throughout life . Since, as already mentioned, GPR17 is only transiently expressed by OPCs and is no longer present in mature myelinating oligodendrocytes (Lecca et al., 2008; Fumagalli et al., 2011; Fumagalli et al., 2015) this transgenic mouse line represents the only possible means to follow in vivo the final destiny of the GPR17 1 pool of OPCs, even after cells have physiologically downregulated the receptor along their differentiation pathway.
We show that, in both models of demyelination, the pool of GPR17 
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| Animal care
For all animal studies, international (European law Dir. 2010/63/UE) and national (Italian law DL n. 26, 4th March 2014) guidelines for the care and use of animals were followed. All the procedures were approved by the Italian Ministry of Health (authorization 473-2015PR to MPA).
Mice were housed in groups of 4, under a 12-hr light/12-hr dark cycle at 218C, with food and water ad libitum. In selected experiments we used wild-type mice (purchased from Charles River, Calco, Italy) or adult animals from the GPR17-iCreER T2 xCAG-eGFP mouse line. In this case mice were maintained and bred at our local facilities. Offspring were ear punched and genotyped using PCR as previously reported . The body weight of the mice was monitored during all experiments.
| Experimental design
The experiments were designed in compliance with the ARRIVE guidelines. Control groups were included in all experiments, randomizing the procedures and applying double-blinded analysis when possible. Sample size was calculated with G-Power, considering a significant level of .05. Based on our preliminary results, to reach a power between 0.80 and 0.90, we needed a minimum of n 5 4 (immunohistochemistry, RT-PCR), depending on the specific experimental conditions. This number is in line to those generally employed in the field.
| EAE induction
EAE was induced in 8-week-old female wild-type C57Bl/6 mice (Charles River) by subcutaneous immunization in the flanks and in the (Miller & Karpus 2007) . Also for this reason, the use of female mice is usually preferred.
| Cuprizone-induced demyelination
Eight-week-old age male C57BL/6 wild-type mice (Charles River) were fed with 0.2% (weight/weight) cuprizone-supplemented diet (SigmaAldrich) ad libitum for 5 weeks and were then switched to normal diet for further 3 weeks to allow spontaneous remyelination (Gudi, Gingele, Skripuletz, & Stangel, 2014) . Immunohistochemistry and qRT-PCR analysis were performed at the beginning of the treatment (W0) and after 1, 3, 5, and 7 weeks. Although the course of de-and remyelination is similar between genders in C57BL/6 mice, the use of male mice is more welldocumented in the literature (Taylor, Gilmore, Ting, & Matsushima, 2010) .
| Tamoxifen induction
Tamoxifen (40 mg/ml; Sigma-Aldrich) was diluted in ethanol (final concentration 10%) and corn oil. Every other day mice received for three times 10 mg of tamoxifen suspension by oral gavaging (for a total of 30 mg) 2 weeks before EAE induction and were sacrificed 21 dpi for histological and real-time PCR analysis. In case of cuprizone-induced demyelination, GFP expression with tamoxifen was induced at week 3, as described above. For the correlation analysis GFP 1 cells were counted in 41 fasciculus gracilis area of EAE mice in whole spinal cord (cervical, thoracic, and lumbar-sacral levels). Fluoromyelin red stain (1:300 in 13 PBS; Thermofisher Scientific, Milan, Italy) was used to selectively label myelin in this area.
Luxol fast blue staining was performed to mark myelin in the corpus callosum of mice (Supporting Information Figure S1 ). In detail, sections were acclimatized at room temperature for 20 min and then dehydrated by passing the slides through growing graded alcoholic solutions (70, 90, 100% EtOH), 2 min each. Slides were then incubated with Luxol Fast Blue solution (Sigma Aldrich; 1 mg/ml in 95% EtOH, 0.5% acetic acid) over-night at 568C. The next day, the excess stain was rinsed off first with 95% EtOH and then with distilled water, 30 s each. The differentiation step was performed first in lithium carbonate solution and then in 70% EtOH, 30 s each, and finally slides were rinsed in distilled water. Differentiation step was repeated till GM was clear and WM sharply defined by the blue stain in control condition.
Hematoxylin (Sigma Aldrich) was used to counterstain sections. Slides were mounted with DPX mountant for histology (Sigma Aldrich).
| In situ hybridization
Slides were dried at room temperature for 5 min. After one wash in 1X
PBS-DEPC, slides were post-fixed in 4% paraformaldehyde for 5 min, Mouse GPR17 cDNA sequences (sense: 5 0 GATGAACGGTCTG-
were inserted in a pBlu2KSM-T vector (Clontech, USA). Digoxigeninlabeled RNA probes were synthesized following the manufacturer's instructions (Roche, Monza, Italy).
| Total RNA extraction, retrotranscription and gene expression analysis
Total RNA was extracted from cells or tissues using Trizol reagent (Life Technologies, Monza, Italy). For gene expression analysis, cDNA synthesis was performed starting from 800 ng of total RNA using SuperScript II Reverse Transcriptase (Life Technologies). The expression of all genes was analysed using Sybr-green reagents (Bio-rad, Milan, Italy) and normalized to GAPDH expression using CFX96 real-time PCR system (Bio-rad) following the manufacturer's protocol. The Ct values were elaborated with the comparative CT method (DDCT) which allows the relative quantification of template comparing the expression levels of the interested gene with the ones of the housekeeping gene.
| Statistical analysis
Data are presented as mean 6 SEM and analyzed with the GraphPad Prism 6.0 software. For all comparisons between two groups with a normal distribution, two-tailed unpaired Student t-test was performed. we confirmed that also in spinal cord, as previously shown for brain (Lecca et al., 2008; Boda et al., 2011; Ceruti et al., 2011) , GPR17 is specifically expressed in a subset of oligodendrocyte precursors at intermediate stages of differentiation.
| GPR17-expressing OPCs respond to EAE induction but do not reach terminal maturation
To unveil disease related changes of GPR17 mRNA and protein, we induced EAE in mice and followed disease development at 10, 20, and 40 days post immunization (DPI). As expected, during EAE development, we observed a progressive loss of cells belonging to the oligodendrocyte lineage. This initial general analysis showed a trend to decrease in the number of OLIG2 1 cells, many of which were also positive for GPR17 that indeed decorated heterogeneous subsets of immature oligodendrocytes (Figure 2a ). For our subsequent studies, we focused on the acute phase, when spinal cord inflammation is high, clinical symptoms severe and the highest decrease in OLIG2 is accompanied by a strong reduction in the number of the GPR17 1 cell pool.
Mice were sacrificed 20 days after EAE induction, spinal cords were explanted and analyzed by both qRT-PCR and immunohistochemistry in both WM and GM.
At this time point, we observed a significant decrease of CC1 Then, we determined the fate of recombined GFP 1 cells after EAE using the same protocol described above. 
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). Data are the mean 6 SEM of cervical, thoracic and lumbar sections; (CTL n 5 3, EAE n 5 5). Unpaired two-tailed Student's t test; ****p < .0001 compared with control from two independent experiments. (e) By means of real-time PCR, a significant up-regulation of GPR17 was found in spinal cord of mice after acute EAE compared with controls and this correlated with the increased expression of inflammatory cytokines (f). Histograms show the fold change value 6 SEM compared with control set to 1. Two-tailed Mann-Whitney student t test, *p .05, **p < .01 from three independent experiments. (g) GPR17 up-regulation was also confirmed by means of in situ hybridization at the lesion site (black arrows) indicate cells with increased levels of Gpr17 mRNA. Scale bar 100 lm. for up to 5 weeks (W) to induce demyelination and were then switched to normal diet to allow spontaneous remyelination. Expression profile of Mbp (b), Gpr17 (c), and IL-1b (d) genes in the corpus callosum during demyelination (1, 3, and 5 weeks of cuprizone diet indicated as W0, W1, W3, and W5) and during the remyelination phase after cuprizone withdrawal (7 weeks, 7W). Mbp expression followed the typical already published pattern, with a marked decrease at W1-W5, followed by recovery at W7; in the case of Gpr17, an initial decrease was followed by increased expression at later phases of demyelination (3W and 5W). Gpr17 up-regulation persisted also after cuprizone withdrawal (W7). As expected, IL-1b expression increased overtime, peaking at W5. Data are the mean 6 SEM of four animals for each timepoint; one-way ANOVA with Tukey's multiple comparison post test; *p < .05, **p < .01, ***p < .001 compared with W0. (e-i) Qualitative immunostaining showing GPR17 expression (in red) during demyelination and remyelination phases in corpus callosum (highlighted by the white dotted lines). The red inset in the brain's drawing refers to the area where the IHC analysis reported in e-i was performed. Scale bar 5 200 mm [Color figure can be viewed at wileyonlinelibrary.com] occurs to a limited extent. Thus, to evaluate the importance of immune activation and inflammation in the changes of GPR17 1 OPCs, we took advantage of the cuprizone model, a toxic-induced demyelination paradigm in which immune system is not involved, inflammation is transient, and the kinetics of both demyelination and the subsequent remyelination phase are clearly defined (Supporting Information Figure S1 ). To this purpose, wild-type mice received a cuprizonesupplemented diet for 5 weeks to cause demyelination and were then switched to normal diet for further 3 weeks to allow spontaneous remyelination ( Figure 6a ). As expected, in corpus callosum expression of the myelin gene Mbp showed typical time-dependent changes consisting in an immediate decrease already evident after 1 week (W1), followed by a rapid recovery after cuprizone withdrawal (Figure 6b ).
Gpr17 expression showed a trend to decrease at W1 followed by rapid and significant upregulation peaking at W5 and returning toward control levels after cuprizone withdrawal (Figure 6c) , with kinetics similar to those of the proinflammatory cytokine IL-1b (Figure 6d ).
The time dependent changes of GPR17 were also confirmed by IHC data. After an initial decrease, due to cuprizone-induced cell loss (W1; Figure 6e ,f), during the demyelination phase we observed a strong accumulation of cells expressing the GPR17 receptor protein in corpus callosum (W3-5; Figure 6g ,h), suggesting that OPCs were responding to damage and started to differentiate.
In line with what observed for the Gpr17 gene (Figure 6c ), during the remyelination phase, the number of GPR17 1 cells in corpus callosum peaked at W5 and then returned to basal levels at W8 (Figure 6i ).
Then, to assess whether, in this demyelinating model, GPR17
1 reacting cells undergo differentiation or stay blocked at immature stages as in the EAE model, we fed GPR17-iCreER T2 xCAG-eGFP mice with cuprizone, and, at W3, induced GFP expression with tamoxifen ( Figure 7a ). This specific timing of tamoxifen administration was chosen to properly monitor the final fate of the OPCs that were expressing GPR17 at the beginning of the OPC proliferation wave (Gudi et al., 2014) . At W8, mice were sacrificed and the maturation stage of the reacting GPR17 1 cells was assessed by double labeling for both GFP and, either NG2 (a marker of oligodendrocyte precursors) or GSTp (a marker of mature oligodendrocytes). Similarly to EAE, a marked increase in the number of GFP 1 cells (Figure 7b-d) was found in the corpus callosum of cuprizone fed mice compared with controls, suggesting a damage-induced expansion of the GPR17 1 pool of cells at W3. In this model, a role for OPCs originating from the subventricular zone (SVZ) has been also suggested (Xing et al., 2014) . However, our staining showed a very low induction of GPR17 in this area (data not shown), suggesting a minor involvement of SVZ-derived GFP 1 cells in the remyelination process. 
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Although the number of GSTp 1 cells was still lower in the corpus callosum of cuprizone fed mice compared with control (Figure 7e ), in the cuprizone group, a significantly higher number of OPCs stained for both GSTp and GFP was found (Figure 7f ), suggesting that many of the OPCs expressing GPR17 at W3 had been able to reach terminal maturation after cuprizone withdrawal. Accordingly, at W8, the number of early GFP 1 precursors still expressing NG2 was lower in the cuprizone group compared with controls ( Figure 7g ).
Globally, these data suggest that, at variance from EAE, in this model of demyelination, GPR17 1 OPCs are able to react to the toxic damage induced by cuprizone administration by first expanding their pool and then progressing to terminally differentiated cells, thus effectively participating to remyelination.
| D I SCUSSION
In recent years, GPR17 has emerged as an important key actor in oligodendrogenesis. Previous studies have shown that, in the brain, GPR17
acts as an intrinsic regulator of this process: indeed, it is necessary to start OPC differentiation but, after a certain stage, it has to be turned down to allow oligodendrocyte terminal maturation (Fumagalli et al., 2015; Fumagalli, Lecca, Coppolino, Parravicini, & Abbracchio, 2017) .
These features have led to the proposal that GPR17 represents a new potential target for remyelination therapies in diseases characterized by myelin disruption such as multiple sclerosis. Here, for the first time, we define the differentiation capabilities of GPR17 1 cells in rodents after myelin disruption in two different models, the former characterized by diffused immune response against myelin components and strong inflammation (the EAE model), and the latter one consisting in local demyelination induced by a toxic agent (the cuprizone model).
In physiological conditions, only a subset of OPCs (typically 30%-40%) express GPR17 (Boda et al., 2011; in both brain and spinal cord, suggesting a role in the normal homeostasis and in oligodendrocyte turnover. Here, we confirm that GPR17 1 cells are widespread throughout the whole spinal cord, both in the GM and WM, showing co-localization with both the early marker NG2 and the more advanced marker CC1.
As expected, in the EAE model, 21-days after immunization, there was a general depletion of oligodendrocytes, as shown by a trend to decrease in OLIG2 1 and GPR17 1 cells (Figure 2a ) and a statistically significant reduction of mature CC1 1 cells (Figure 2b ), suggesting that mature oligodendrocytes are likely to be more affected by disease induction. At this stage, the total number of spinal cord NG2 1 cells was unaltered in both the GM and WM (Figure 2c ). However, double immunofluorescence analysis on these precursors showed that the NG2 1 / GPR17 1 subpopulation was increased in the WM but not in the GM, which was indeed relatively spared (Figure 3a ), demonstrating that, (i) the GPR17 (Figure 7f ). In EAE spinal cord, significant maturation of GPR17 1 cells was only observed in the GM (Figure 5g) (Gudi et al., 2014) .
Of course, we cannot exclude that such differential responses can also be due, at least in part, to different OPCs intrinsic programs in spinal cord and corpus callosum. Adult OPCs indeed originate from evolutionary distinct populations, and for this reason they keep different physiological features and capabilities to respond to demyelination for their whole life (Ornelas et al., 2016) . populations as a continuum in the differentiation process suggesting that the term "OPCs" represents a strong approximation of the actual genic and functional diversity of these cells. Of interest, GPR17 was identified in three of these populations defined as "differentiation committed precursors" (Marques et al., 2016) . This confirms that our GPR17 reporter mouse line is a useful tool to fate-map a specific subpopulation of intermediate precursors committed to maturation, rather than simply highlighting a general "prototypic" early response of NG2-cells.
Interestingly, the lack of OPC terminal maturation in EAE tissues is also accompanied by persistent GPR17 overexpression. As already mentioned, while GPR17 is needed to start differentiation, its chronic overexpression due to impaired physiological downregulation has been associated to OPC blockade and impaired remyelination (Fumagalli et al., 2015; Ou et al., 2016) . Besides EAE (the present study), several other distinct models of brain disease, including stroke, trauma, Alzheimer's (Fumagalli et al., 2016) have been associated to persistent GPR17 upregulation and impaired progression along the oligodendrocyte lineage, eventually resulting in dysfunctional repair. Importantly, GPR17 has been shown to "promiscuously" respond to several different proinflammatory ligands accumulating at injury sites (Sensi et al., 2014; Parravicini et al., 2016) , not only uracil nucleotides and cysteinylleukotrienes (Ciana et al., 2006) , but also oxysterols and CXCL12 (Parravicini et al., 2016) , one of the most prominent chemokines in the lesions of multiple sclerosis patients (Calderon et al., 2006) . In a permissive environment, these inflammatory stimuli could initially contribute to promotion of remyelination through GPR17 stimulation, in line with literature data proposing that acute inflammation triggers remyelination (Foote & Blakemore 2005) . However, when inflammation becomes stronger and chronic (as it occurs when EAE is overtly symptomatic), this beneficial effect is turned into a detrimental condition (Marchetti & Abbracchio 2005 ) that worsens rather than favor, remyelination. In line with this hypothesis, the strong inflammatory milieu associated to the degenerative conditions mentioned above is accompanied by GPR17 upregulation (Fumagalli et al., 2015) , which prevents terminal OPC maturation and remyelination.
Based on the above evidence, on the strikingly different contribution of inflammation to EAE-and cuprizone-induced demyelination (Denic et al., 2011; Gudi et al., 2014) , and based on the different capability of GPR17 1 OPCs to undergo maturation in these two rodent models (the present results), we speculate that the proinflammatory local environment associated to EAE induction is responsible for persistent GPR17 overexpression in OPCs, leading to their blockade at immature stages.
Our data open new directions to treat demyelination in neuroinflammatory diseases, such as multiple sclerosis, in which inappropriate resolution of acute inflammation leads to its chronicization. They also suggest that remyelinating approaches should be combined to therapies controlling chronic inflammation, in order to achieve effective myelin repair and retard neurodegeneration.
